SOURCE: Geneart AG

January 28, 2008 08:49 ET

GENEART supports the Craig Venter Institute to create the first synthetic bacterial genome

- GENEART supplied parts of the building blocks to construct the bacterial genome, which is 580,000 base pairs in length

- This is the first time a complete synthetic bacterial genome was created in a laboratory

- The economic potential of synthetic biology is gaining greater visibility

REGENSBURG, GERMANY--(Marketwire - January 28, 2008) - GENEART AG, the global market leader in gene synthesis and specialist in the field of synthetic biology, is announcing that parts of the first synthetic bacterial genome created by the Craig Venter Institute were produced in the laboratories of the Regensburg Company. Craig Venter has reached a milestone in the synthetic biology field by creating the genome, with a length of 580,000 base pairs. The research results, which were published in the "Science" professional journal last Thursday, provide the necessary basis to create tailor-made bacteria for applications such as producing low-cost, environmentally friendly biofuels, efficiently manufacturing complex biopharmaceuticals, or breaking down pollutants. This represents another important step towards making synthetic biology available for commercial applications.

"The achievements of the Craig Venter Institute clearly illustrate the tremendous potential of synthetic biology applications. As the global leader in the gene synthesis field, with a monthly capacity of approximately 2 million base pairs for the building blocks, we have established a key technology platform in order to help drive these developments. In addition, we will also be supporting our customers in the development of efficient bio-factories by synthesising functional gene clusters (so-called operons). Our laboratories are working on corresponding research projects, some of which are publicly-funded, at full speed. Thus we will consistently develop our ability to create an added value for this industry," says Prof. Dr. Ralf Wagner, CEO of GENEART AG.

Legal Information

This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.


In 2000, GENEART entered the gene synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the synthetic biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. Our production and service spectrum spans a wide range, from the production of synthetic genes according to DIN EN ISO 9001-2000, to the creation of gene libraries in the combinatorial biology, to the development and production of DNA-based biologically active substances. The GENEART AG in Regensburg (Germany) and the subsidiary GENEART Inc. in Toronto (Canada) employ more than 190 people. Since May 2006, GENEART is listed on the German Stock Exchange.

Copyright © Hugin AS 2008. All rights reserved.

Contact Information

  • For further inquiries, please contact:

    Bernd Merkl
    Josef-Engert-Str. 11
    93053 Regensburg
    Phone: +49-(0)941-942 76-638
    Fax: +49-(0)941-942 76-711
    Email Contact

    Frank Ostermair
    Better Orange IR & HV AG
    Haidelweg 48
    81241 Munich
    Email Contact